|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 1/17/2024
Contributor(s): Jack Arbiser
|
|
Small Molecules for Treating Cystic Fibrosis
ApplicationSmall molecule compounds to potentiate most common type of CFTR mutation in cystic fibrosis patients.Key BenefitsPotentiates ΔF508-hCFTR mutation, addressing more than 60 percent of CF patients. Market SummaryCystic fibrosis transmembrane conductance regulator (CFTR) is a membrane protein and ion channel that malfunctions in the genetic...
Published: 7/28/2023
Contributor(s): Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
|
|
Quinazolin-4(3H)-one Derivatives as NOX-2 Inhibitors: Composition of Matter, Methods of Preparation and Their Use
Application
Quinazolin-4(3H)-one derivatives as selective NOX-2 inhibitors to prevent oxidative damage.
Key Benefits
Small molecule NOX-2 specific inhibitor.
Prevents excessive reactive oxygen species (ROS) generation rather than removing them.
Selective NOX-2 inhibition offers significant advantages to development of an effective therapy against...
Published: 4/23/2024
Contributor(s): Thota Ganesh, Radhika Amaradhi, Jacek Zielonka
|
|
Discovery of A Dual Inhibitor of NQO1 and GSTP1 for Treating Malignant Glioblastoma
Application
A small molecule compound to treat Malignant Glioblastoma multiforme.
Key Benefits
Dual inhibition of NQO1 and GSTP1 induces cell death in glioblastoma cells.
Inhibition of NQO1 and GSTP1 by MNPC suppresses tumor growth and elongates the life span of the animals with GBM.
Market Summary
Approximately 30% of patients diagnosed with...
Published: 4/23/2024
Contributor(s): Keqiang Ye
|
|
Use of miRNA-483 and its Target Genes in Treatment of Cardiovascular and Inflammatory Diseases
Application
Therapeutic use of miR-483 mimic for treating aortic valve clarification.
Key Benefits
MiR-483 or mimics of miR-483 could be used as a therapeutic.
Could also be a target for additional drug development toward a non-invasive therapy for aortic valve calcification.
Market Summary
Aortic stenosis (AS) is the most common type of heart...
Published: 4/8/2024
Contributor(s): Hanjoong Jo, Joan Fernandez Esmerats, Nicolas (Nico) Villa-Roel
|
|
Novel Piperidine-Amide Derivatives as CXCR4 Modulators
Application
A new class of CXCR4 modulators for metastasis and inflammation.
Key Benefits
Selective for only one allosteric site on CXCR4.
Lower adverse effects.
Market Summary
Activation of the CXCR4 receptor triggers multiple signaling pathways that orchestrate cell migration, hematopoiesis and cell homing, and retention in the bone...
Published: 11/27/2023
Contributor(s): Hyunsuk Shim, Yoon Hyeun Oum
|
|
Small Molecule Compound to Treat Neurological Diseases
Application
NMDAR agents for the treatment of various neurological diseases.
Key Benefits
Exemplary compound EU1180-490 is a potent and selective potentiator of GluN1/GluN3 NMDARs.
The compound has excellent Lipinski drug-like properties including low molecular weight and cLogP, as well as water solubility.
The initial studies have determined...
Published: 4/23/2024
Contributor(s): Dennis Liotta, Stephen Traynelis, Hongjie Yuan, Matthew Epplin, Samantha Summer, David Menaldino, Leon Jacobs, Adam McCallum
|
|
Small Molecules as Disinfectants and Antiseptics
Application
Anti-microbial molecules with broad spectrum activities.
Key Benefits
Effective antimicrobial scaffolds with improved broad-spectrum activities compared to current commercial disinfectants.
Market Summary
There is an increased effort in developing new antibiotics, antiseptics, and disinfectants to overcome the current resistance...
Published: 4/8/2024
Contributor(s): William (Bill) Wuest, Kevin Minbiole
|
|
CFTR Modulators for Treating Rare Forms of Cystic Fibrosis
Application
Small molecules to treat cystic fibrosis and other pulmonary diseases.
Key Benefits
Rescue rare variants of CFTR gene.
Serve as PDE4 inhibitors with strong anti-inflammatory effects.
Market Summary
Cystic fibrosis (CF) is a progressive, genetic disorder that arises from mutations in the cystic fibrosis transmembrane conductance...
Published: 4/8/2024
Contributor(s): Eric J. Sorscher, Jeong Hong, Haian Fu, Yuhong Du, Huw Davies, Andras Rab, Candela Manfredi, Xun Yang, Zhi Ren
|
|
Class of Bcl-2 Inhibitors as Anti-Cancer Therapeutics
Application
Small molecule inhibitors of Bcl-2, an anti-apoptotic protein, for cancer treatment.
Key Benefits
Developed specifically to target the BH4 homology domain of Bcl-2 in order to improve binding affinity and anti-tumor efficacy over other Bcl-2 inhibitors.
Compounds may simultaneously suppress a wider range of anti-apoptotic proteins...
Published: 4/23/2024
Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
|